Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study.

Eur Arch Otorhinolaryngol · 2025 · PMC12518420 · PMID 40736677

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this study, the adjuvant immunotherapy showed a trend towards improving the survival of patients with LA-HNSCC who have intermediate- and high-risk factors; however, the statistical difference was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.